Patient-Reported Outcome Questionnaire for Systemic Mastocytosis

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

5 participants

Study Classification

OBSERVATIONAL

Study Start Date

2014-07-31

Study Completion Date

2015-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to explore the key symptoms of individuals with systemic mastocytosis. Interviews of enrolled individuals will be conducted to learn about the disease symptoms and condition. The interview will last approximately 60 minutes and will be conducted by a trained interviewer, be audio-recorded (with patient consent), and all information provided by the patient will be treated confidentially and made anonymous so that it is non-identifiable. The interview may be conducted face-to-face, over the phone, or virtually via Skype, a free video conferencing program, depending upon the patient's geographic location. Patients will be compensated for their participating time.

This is not a medication-related study, and no medication will be distributed or tested during this study. Participation in this study will not affect any treatment or assistance that a patient currently receives or may receive in the future.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

An Observational Study in Participants With Indolent Systemic Mastocytosis (ISM)

NCT07264959

Indolent Systemic Mastocytosis

NOT_YET_RECRUITING

Masitinib in Severe Indolent or Smoldering Systemic Mastocytosis Unresponsive to Optimal Symptomatic Treatment

NCT04333108

Indolent Systemic Mastocytosis

UNKNOWN PHASE3

Safety and Efficacy of Subcutaneous Sarilumab in Improving the Quality of Life in People With Indolent Systemic Mastocytosis

NCT03770273

Indolent Systemic Mastocytosis

COMPLETED PHASE2

Screening Study for KIT D816V Mutated Mast Cell Disease in Select Populations

NCT07143669

Clonal Mast Cell Disease KIT D816V Mutation Suspected KITD816V Mutated Clonal Mast Cell Disease

RECRUITING

Epidemiological Data on Mast Cell Pathologies in France

NCT06186856

Mast Cell Disorder

RECRUITING

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Aggressive Systemic Mastocytosis (ASM) SM w Assoc Clonal Hema Non-mast Cell Lineage Disease (SM-AHNMD) Mast Cell Leukemia (MCL) Smoldering Systemic Mastocytosis (SSM) Indolent Systemic Mastocytosis (ISM) ISM Subgroup Fully Recruited

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_ONLY

Study Time Perspective

CROSS_SECTIONAL

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.